| Ident. | Authors (with country if any) | Title |
|---|
| 000332 |
Gilles Lambert [France, Australie] ; Francine Petrides [Australie] ; Mathias Chatelais [France] ; Dirk J. Blom [Afrique du Sud] ; Benjamin Choque [Australie] ; Fatiha Tabet [Australie] ; Gida Wong [Australie] ; Kerry-Anne Rye [Australie] ; Amanda J. Hooper [Australie] ; John R. Burnett [Australie] ; Philip J. Barter [Australie] ; A. David Marais [Afrique du Sud] | Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects |
| 000E54 |
François Guilhot [France] ; Timothy P. Hughes [Australie] ; Jorge Cortes [États-Unis] ; Brian J. Druker [États-Unis] ; Michele Baccarani [Italie] ; Insa Gathmann [Suisse] ; Michael Hayes [États-Unis] ; Camille Granvil [États-Unis] ; YANFENG WANG [États-Unis] | Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial |
| 000E55 |
Roeland Huijgen [Pays-Bas] ; S. Matthijs Boekholdt [Pays-Bas] ; Benoit J. Arsenault [Pays-Bas] ; WEIHANG BAO [États-Unis] ; Jean-Michel Davaine [France] ; Fatiha Tabet [Australie] ; Francine Petrides [Australie] ; Kerry-Anne Rye [Australie] ; David A. Demicco [États-Unis] ; Philip J. Barter [Australie] ; John J. P. Kastelein [Pays-Bas] ; Gilles Lambert [France, Australie] | Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study |
| 001C69 |
J. M. Frazao [Portugal] ; P. Messa [Italie] ; G. J. Mellotte [Irlande (pays)] ; H. Geiger [Allemagne] ; E. C. Hagen [Pays-Bas] ; L. D. Quarles [États-Unis] ; P. G. Kerr [Australie] ; A. Banos [Suisse] ; B. Dehmel [Suisse] ; P. Urena [France] | Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity |
| 002916 |
Dilo Pillai [Australie] ; H. Alec Ross [Pays-Bas] ; Jürgen Kratzsch [Allemagne] ; William Pedrosa [Brésil] ; Ido Kema [Pays-Bas] ; Kirsten Hoad [Australie] ; Nathalie Rouaix [France] ; Marc Fathi [Suisse] ; Herbert Nader [Allemagne] ; Bruno Mathian [France] ; Eric Grouzmann [Suisse] | Proficiency test of plasma free and total metanephrines: report from a study group |
| 002931 |
Dick C. Chan [Australie] ; Gilles Lambert [Australie, France] ; P. Hugh R. Barrett [Australie] ; Kerry-Anne Rye [Australie] ; Esther M. M. Ooi [Australie] ; Gerald F. Watts [Australie] | Plasma Proprotein Convertase Subtilisin/ Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism? |
| 002C43 |
Patrick Van Dreden [France] ; Aurélie Rousseau [France] ; Sylviane Fontaine [France] ; Barry J. Woodhams [France] ; Thomas Exner [Australie] | Clinical evaluation of a new functional test for detection of plasma procoagulant phospholipids |
| 002D05 |
Duncan J. Campbell [Australie] ; Juerg Nussberger [Suisse] ; Michael Stowasser [Australie] ; A. H. Jan Danser [Pays-Bas] ; Alberto Morganti [Italie] ; Erik Frandsen [Danemark] ; Joël Menard [France] | Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement |
| 002F98 |
Gilles Lambert [Australie, France] ; Nicolas Ancellin [France] ; Francesca Charlton [Australie] ; Daniel Comas [France] ; Julia Pilot [France] ; Anthony Keech [Australie] ; Sanjay Patel [Australie] ; David R. Sullivan [Australie] ; Jeffrey S. Cohn [Australie] ; Kerry-Anne Rye [Australie] ; Philip J. Batter [Australie] | Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment |
| 003B08 |
Vanessa M. Hayes [Australie] ; Gianluca Severi [Australie] ; Emma J. D. Padilla [Australie] ; Howard A. Morris [Australie] ; Wayne D. Tilley [Australie] ; Melissa C. Southey [Australie, France] ; Dallas R. English [Australie] ; Robert L. Sutherland [Australie] ; John L. Hopper [Australie] ; Peter Boyle [France] ; Graham G. Giles [Australie] | 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia |
| 004149 |
Claudine Mazurier [France] | Composition, quality control, and labeling of plasma-derived products for the treatment of von willebrand disease |
| 004446 |
Pierre Amarenco [France] ; Anushka Patel [France] ; Mark Woodward [France] ; Duncan J. Campbell [Australie] ; David R. Sullivan [Australie] ; Samuel Colman [France] ; John Chalmers [France] ; Bruce Neal [France] ; Stephen Macmahon [France] | Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease |
| 004F96 |
Armin Imhof [Allemagne] ; Margit Fröhlich [Allemagne] ; Hannelore Loewel [Allemagne] ; Nicole Helbecqae [France] ; Mark Woodward [Australie] ; Phillipe Amouyel [France] ; Gordon D. O. Lowe [Royaume-Uni] ; Wolfgang Koenig [Allemagne] | Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe |
| 005A37 |
Santica M. Marcovina [États-Unis] ; John J. Albers [États-Unis] ; Angelo M. Scanu [États-Unis] ; Hal Kennedy [États-Unis] ; Federico Giaculli [États-Unis] ; Kare Berg [Norvège] ; Rémy Couderc [France] ; Francesco Dati [Allemagne] ; Nader Rifai [États-Unis] ; Ikunosuke Sakurabayashi [Japon] ; Jillian R. Tate [Australie] ; Armin Steinmetz [Allemagne] | Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a) |
| 005B15 |
F. Milliat [France] ; D. Gripois [France] ; M.-F. Blouquit [France] ; J. Ferezou [France] ; C. Serougne [France] ; N.-H. Fidge [Australie] ; C. Lutton [France] | Short and long-term effects of streptozotocin on dietary cholesterol absorption, plasma lipoproteins and liver lipoprotein receptors in RICO rats |
| 005D48 |
H. M. Dodds [Australie] ; S. J. Clarke [Australie] ; M. Findlay [Nouvelle-Zélande] ; J. F. Bishop [Australie] ; J. Robert [France] ; L. P. Rivory [Australie] | Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance |
| 006239 |
H. M. Dodds [Australie] ; J. Robert [France] ; L. P. Rivory [Australie] | The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry |
| 006374 |
P. Z. Zimmet [Australie] ; V. R. Collins [Australie] ; M. P. De Courten [Australie] ; A. M. Hodge [Australie] ; G. R. Collier [Australie] ; G. K. Dowse [Australie] ; K. G. M. M. Alberti [Royaume-Uni] ; J. Tuomilehto [Finlande] ; F. Hemraj [France] ; H. Gareeboo [France] ; P. Chitson [France] ; D. Fareed [Maurice (pays)] | Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius |
| 006456 |
G. Pearce [Australie] ; D. A. Tabensky [Australie] ; P. D. Delmas [France] ; H. W. G. Baker [Australie] ; E. Seeman [Australie] | Corticosteroid-induced bone loss in men |
| 006658 |
L. P. Rivory [Australie] ; M.-C. Haaz [France] ; P. Canal [France] ; F. Lokiec [France] ; J.-P. Armand [France] ; J. Robert [France] | Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials |
| 006665 |
P. Baille [France] ; R. Bruno [France] ; J. H. M. Schellens [Pays-Bas] ; L. K. Webster [Australie] ; M. Millward [Australie] ; J. Verweij [Pays-Bas] ; G. Montay [France] | Optimal sampling strategies for bayesian estimation of docetaxel (taxotere) clearance |
| 006757 |
R. Nowak [France] ; T. M. Murphy [Australie] ; D. R. Lindsay [Australie] ; P. Alster [Suède] ; R. Andersson [Suède] ; K. Uvn S-Moberg [Suède] | Development of a preferential relationship with the mother by the newborn lamb : Importance of the sucking activity |
| 006935 |
L. P. Rivory [Australie, France] ; J.-F. Riou [États-Unis] ; M.-C. Haaz [France] ; S. Sable [États-Unis] ; M. Vuilhorgne [États-Unis] ; A. Commercon [États-Unis] ; S. M. Pond [Australie] ; J. Robert [France] | Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients |
| 006D73 |
R. Sanson-Fisher [Australie] ; J. Bowman ; S. Armstrong | Factors affecting nonadherence with antibiotics |
